Lack of thyroid hormone receptor beta is not detrimental for non-alcoholic steatohepatitis progression

Nuria Lopez-Alcantara; Rebecca Oelkrug; Sarah Christine Sentis; Henriette Kirchner; Jens Mittag

doi:10.1016/j.isci.2023.108064

Lack of thyroid hormone receptor beta is not detrimental for non-alcoholic steatohepatitis progression

Nuria Lopez-Alcantara, Rebecca Oelkrug, Sarah Christine Sentis, Henriette Kirchner, Jens Mittag^*

^*Korrespondierende/r Autor/-in für diese Arbeit

11 Zitate (Scopus)

Abstract

Agonists for thyroid hormone receptor β (TRβ) show promise in preclinical studies and clinical trials to improve non-alcoholic fatty liver disease. A recent study on human livers, however, revealed reduced TRβ expression in non-alcoholic steatohepatitis (NASH), indicating a developing thyroid hormone resistance, which could constitute a major obstacle for those agonists. Using a rapid NASH paradigm combining choline-deficient high-fat diet and thermoneutrality, we confirm that TRβ declines during disease progression in mice similar to humans. Contrary to expectations, mice lacking TRβ showed less liver fibrosis, and NASH marker genes were not elevated. Conversely, increasing TRβ expression in wild-type NASH mice using liver-targeted gene therapy did not improve histology, gene expression, or metabolic parameters, indicating that TRβ receptor levels are of minor relevance for NASH development and progression in our model, and suggest that liver—rather than isoform—specificity might be more relevant for NASH treatment with thyroid hormone receptor agonists.

Originalsprache	Englisch
Aufsatznummer	108064
Zeitschrift	iScience
Jahrgang	26
Ausgabenummer	10
Seiten (von - bis)	108064
ISSN	2589-0042
DOIs	https://doi.org/10.1016/j.isci.2023.108064
Publikationsstatus	Veröffentlicht - 20.10.2023

Fördermittel

We thank the Gemeinsame Tierhaltung at the University of Lübeck for excellent animal caretaking. The technical support of Julia Resch from the University of Lübeck and An Ruiter and Marinne Frans from the Endocrine Laboratory Amsterdam UMC is greatly appreciated. We also appreciate the input of Timo Müller from the Helmholtz Munich for the development of the NASH model. The work was funded by the Deutsche Forschungsgemeinschaft (DFG) in the framework of the TRR296 “Local Control of Thyroid Hormone Action” to J.M. (Project-ID 424957847) and in an individual grant to R.O. (Project-ID 434396546). S.C.S. is a student of the DFG funded GRK1957 “Adipocyte-Brain-Crosstalk”. N.L.A. R.O. and S.C.S. conducted experiments; N.L.A. R.O. S.C.S. H.K. and J.M. analyzed the data; H.K. and J.M. supervised and designed the study; N.L.A. and J.M. drafted the manuscript. All authors discussed, corrected, and approved the manuscript. The authors declare no competing interests. We support inclusive, diverse, and equitable conduct of research. We thank the Gemeinsame Tierhaltung at the University of Lübeck for excellent animal caretaking. The technical support of Julia Resch from the University of Lübeck and An Ruiter and Marinne Frans from the Endocrine Laboratory Amsterdam UMC is greatly appreciated. We also appreciate the input of Timo Müller from the Helmholtz Munich for the development of the NASH model. The work was funded by the Deutsche Forschungsgemeinschaft ( DFG ) in the framework of the TRR296 “ Local Control of Thyroid Hormone Action ” to J.M. (Project-ID 424957847 ) and in an individual grant to R.O. (Project-ID 434396546 ). S.C.S . is a student of the DFG funded GRK1957 “ Adipocyte-Brain-Crosstalk ”.

Strategische Forschungsbereiche und Zentren

Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)

DFG-Fachsystematik

2.22-17 Endokrinologie, Diabetologie, Metabolismus

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

Dokumente

10.1016/j.isci.2023.108064

Weitere Links

SFB/TRR 296 LocoTact: Lokale Kontrolle der Schilddrüsenhormonwirkung
Führer-Sakel, D. (Sprecher*in, Koordinator*in), Mittag, J. (Stellv. Sprecher*in, Co-Sprecher*in), Kühnen, P. (Stellv. Sprecher*in, Co-Sprecher*in), Heuer, H. (Projektleiter*in (PI)), Schwaninger, M. (Projektleiter*in (PI)), Müller-Fielitz, H. (Projektleiter*in (PI)), Bechmann, I. (Projektleiter*in (PI)), Biebermann, H. (Projektleiter*in (PI)), Müller, T. (Projektleiter*in (PI)), Pfluger, P. (Projektleiter*in (PI)), Krude, H. (Projektleiter*in (PI)), Schülke-Gerstenfeld, M. (Projektleiter*in (PI)), Cirkel, A. (Projektleiter*in (PI)), Münte, T. (Projektleiter*in (PI)), Kleinschnitz, C. (Projektleiter*in (PI)), Langhauser, F. (Projektleiter*in (PI)), Engel, D. R. (Projektleiter*in (PI)), Möller, L. (Projektleiter*in (PI)), Kaiser, F. (Projektleiter*in (PI)), Oster, H. (Projektleiter*in (PI)), Kirchner, H. (Projektleiter*in (PI)), Spranger, J. (Projektleiter*in (PI)), Tacke, F. (Projektleiter*in (PI)), Wirth, E. K. (Projektleiter*in (PI)), Köhrle, J. (Projektleiter*in (PI)), Schomburg, L. (Projektleiter*in (PI)), Lange, C. M. (Projektleiter*in (PI)), Zwanziger, D. (Projektleiter*in (PI)), Mayerl, S. (Projektleiter*in (PI)), Stachelscheid, H. (Projektleiter*in (PI)), Opitz, R. (Projektleiter*in (PI)), Prasuhn, J. (Projektleiter*in (PI)), Lorenz, K. (Projektleiter*in (PI)), Köster, J. (Projektleiter*in (PI)), Mai, K. (Projektleiter*in (PI)), Püngel, T. (Projektleiter*in (PI)), Obermayer, B. (Projektleiter*in (PI)) & Rehwald, S. (Projektleiter*in (PI))
01.01.20 → 31.12.25
Projekt: DFG Verbundprojekte › DFG Sonderforschungsbereiche / Transregios (SFB/TR)

Zitieren

@article{8839f056831e45ba8ef891e4243ff1e2,

title = "Lack of thyroid hormone receptor beta is not detrimental for non-alcoholic steatohepatitis progression",

abstract = "Agonists for thyroid hormone receptor β (TRβ) show promise in preclinical studies and clinical trials to improve non-alcoholic fatty liver disease. A recent study on human livers, however, revealed reduced TRβ expression in non-alcoholic steatohepatitis (NASH), indicating a developing thyroid hormone resistance, which could constitute a major obstacle for those agonists. Using a rapid NASH paradigm combining choline-deficient high-fat diet and thermoneutrality, we confirm that TRβ declines during disease progression in mice similar to humans. Contrary to expectations, mice lacking TRβ showed less liver fibrosis, and NASH marker genes were not elevated. Conversely, increasing TRβ expression in wild-type NASH mice using liver-targeted gene therapy did not improve histology, gene expression, or metabolic parameters, indicating that TRβ receptor levels are of minor relevance for NASH development and progression in our model, and suggest that liver—rather than isoform—specificity might be more relevant for NASH treatment with thyroid hormone receptor agonists.",

author = "Nuria Lopez-Alcantara and Rebecca Oelkrug and Sentis, \{Sarah Christine\} and Henriette Kirchner and Jens Mittag",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s)",

year = "2023",

month = oct,

day = "20",

doi = "10.1016/j.isci.2023.108064",

language = "English",

volume = "26",

pages = "108064",

journal = " iScience",

issn = "2589-0042",

number = "10",

}

TY - JOUR

T1 - Lack of thyroid hormone receptor beta is not detrimental for non-alcoholic steatohepatitis progression

AU - Lopez-Alcantara, Nuria

AU - Oelkrug, Rebecca

AU - Sentis, Sarah Christine

AU - Kirchner, Henriette

AU - Mittag, Jens

PY - 2023/10/20

Y1 - 2023/10/20

N2 - Agonists for thyroid hormone receptor β (TRβ) show promise in preclinical studies and clinical trials to improve non-alcoholic fatty liver disease. A recent study on human livers, however, revealed reduced TRβ expression in non-alcoholic steatohepatitis (NASH), indicating a developing thyroid hormone resistance, which could constitute a major obstacle for those agonists. Using a rapid NASH paradigm combining choline-deficient high-fat diet and thermoneutrality, we confirm that TRβ declines during disease progression in mice similar to humans. Contrary to expectations, mice lacking TRβ showed less liver fibrosis, and NASH marker genes were not elevated. Conversely, increasing TRβ expression in wild-type NASH mice using liver-targeted gene therapy did not improve histology, gene expression, or metabolic parameters, indicating that TRβ receptor levels are of minor relevance for NASH development and progression in our model, and suggest that liver—rather than isoform—specificity might be more relevant for NASH treatment with thyroid hormone receptor agonists.

AB - Agonists for thyroid hormone receptor β (TRβ) show promise in preclinical studies and clinical trials to improve non-alcoholic fatty liver disease. A recent study on human livers, however, revealed reduced TRβ expression in non-alcoholic steatohepatitis (NASH), indicating a developing thyroid hormone resistance, which could constitute a major obstacle for those agonists. Using a rapid NASH paradigm combining choline-deficient high-fat diet and thermoneutrality, we confirm that TRβ declines during disease progression in mice similar to humans. Contrary to expectations, mice lacking TRβ showed less liver fibrosis, and NASH marker genes were not elevated. Conversely, increasing TRβ expression in wild-type NASH mice using liver-targeted gene therapy did not improve histology, gene expression, or metabolic parameters, indicating that TRβ receptor levels are of minor relevance for NASH development and progression in our model, and suggest that liver—rather than isoform—specificity might be more relevant for NASH treatment with thyroid hormone receptor agonists.

UR - https://www.scopus.com/pages/publications/85173145686

UR - https://www.mendeley.com/catalogue/dcdf91c4-ca24-316e-821c-a39729ab4d85/

U2 - 10.1016/j.isci.2023.108064

DO - 10.1016/j.isci.2023.108064

M3 - Journal articles

C2 - 37822510

AN - SCOPUS:85173145686

SN - 2589-0042

VL - 26

SP - 108064

JO - iScience

JF - iScience

IS - 10

M1 - 108064

ER -

Lack of thyroid hormone receptor beta is not detrimental for non-alcoholic steatohepatitis progression

Abstract

Fördermittel

Strategische Forschungsbereiche und Zentren

DFG-Fachsystematik

UN SDGs

Dokumente

Weitere Links

Fingerprint

Projekte

SFB/TRR 296 LocoTact: Lokale Kontrolle der Schilddrüsenhormonwirkung

Zitieren